From the Research
NAD (nicotinamide adenine dinucleotide) loading via subcutaneous injection typically involves administering 500-1000mg of NAD+ daily for 5-10 days to rapidly increase cellular NAD+ levels, as supported by recent studies on NAD+ precursors and their therapeutic potential 1, 2, 3. The subcutaneous route allows for slower absorption compared to IV administration, potentially reducing side effects like flushing and nausea while maintaining effectiveness. Some key points to consider when administering NAD+ subcutaneously include:
- Diluting NAD+ in sterile saline to a concentration of 100-200mg/mL
- Injecting into the fatty tissue of the abdomen, thigh, or upper arm using a small gauge needle (27-30G)
- Limiting each injection site to no more than 1-2mL of solution, with multiple sites used for larger doses After the loading phase, maintenance doses of 100-200mg once or twice weekly are typically recommended. NAD+ functions as a critical coenzyme in cellular metabolism, and the loading phase aims to rapidly restore depleted levels to improve mitochondrial function, energy production, and cellular repair mechanisms. While generally considered safe, patients should be monitored for injection site reactions, and the procedure should be performed using sterile technique, as noted in studies on the safety and efficacy of NAD+ administration 4, 3. It is essential to prioritize the patient's safety and well-being, and to consult the most recent and highest-quality studies, such as those published in reputable journals like Antioxidants & Redox Signaling 1 and Pharmaceuticals (Basel, Switzerland) 3, to inform treatment decisions.